2025 SABCS Highlights: Advances in Oral SERDs for Breast Cancer | Dana-Farber Cancer Institute
🛍️ Products Mentioned (1)
Harold Burstein, MD, PhD, and Rinath M. Jeselsohn, MD, discuss the lidERA, evERA, and EMBER-3 trials researching oral selective estrogen receptor degraders (SERDs). For more information about Dana-Farber's Breast Oncology Center, visit https://www.dana-farber.org/cancer-care/treatment/breast-oncology
🎬 More from Dana-Farber Cancer Institute
Understanding Chemo Neuropathy: A Webinar by the Older Adults with GI Cancer Program | Dana-Farber
19 views
Learning About Chronic Lymphocytic Leukemia | Lymph Notes: A Lymphoma Learning Series
112 views
ASCO26: David Reardon, MD Glioblastoma Vaccine | Dana-Farber Cancer Institute
106 views
Society of Gynaecological Oncology Congress 2026: Tara Berman, MD | Dana-Farber Cancer Institute
30 views
ASCO26: Julia Rotow, MD Silevertinib in Lung Cancer | Dana-Farber Cancer Institute
55 views
ASCO26: Atish Choudhury, MD, PhD A-DREAM/Alliance A032101 | Dana-Farber Cancer Institute
38 views